US industry seeks clarification of SUDs (single-use devices) reuse rules
This article was originally published in Clinica
The US FDA should demand to see validation data for nearly all reused single-use devices (SUDs), US industry officials have concluded, after learning that nearly half of the products that were subject to such data have been pulled from the market because there was no proof they could be adequately cleaned and sterilised.
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.